EBV AND CMV INFECTION IN RECIPIENTS OF HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION RECEIVING TWO DIFFERENT DOSES OF ANTITHYMOCYTEGLOBULIN AS CONDITIONING REGIMEN
(Abstract release date: 05/19/16)
EHA Library. Liu Q. 06/09/16; 133072; E1523
Prof. Qifa Liu
Contributions
Contributions
Abstract
Abstract: E1523
Type: Eposter Presentation
Background
Antithymocyteglobulin (ATG) has been widely used to prevent acute graft-versus-host disease (aGVHD) in recipients receiving haploidentical hematopoietic stem cell transplantation (HSCT). Notwithstanding, immunosuppressive effect of ATG increases the risk for infections, especially viral infection. Therefore, the optimal dose of ATG which elicits adequate immune suppression and limits the development of viral infection/reactivation is needed to be studied.
Aims
To evaluate the effect of different doses of ATG on post-transplant viral infection, this multicenter prospective study was conducted to compare EBV and CMV infection in haploidentical HSCT recipients receiving 7.5 mg/kg or 10 mg/kg of ATG. Besides, the incidence of aGVHD was compared between the two arms.
Methods
Between January 2013 and August 2015, 217 consecutive patients with hematological malignancies undergoing haploidentical HSCT were enrolled in 4 hospitals. One hundred and ten patients were randomized to receive a total dosage of 7.5 mg/kg of ATG and 107 were randomized to receive 10 mg/kg of ATG.
Results
The 1-year cumulative incidence of EBV infection were 30.7±6.0% in 7.5 mg/kg of ATG arm and 43.1±6.0% in 10 mg/kg arm (P=0.107). CMV infection were comparable in the two arms (7.5 mg/kg arm: 79.6±3.9% vs 10 mg/kg arm: 84.1±3.6%, P=0.188). Acute GVHD grade II to IV within 100 days occurred in 35.9±5.2% of the patients with 7.5 mg/kg ATG and 19.2±4.8% of those with 10 mg/kg ATG (P=0.004). The incidence of aGVHD grade III to IV within day 100 were 14.1±3.9% in 7.5 mg/kg arm and 7.3±3.3% in 10 mg/kg arm (P=0.072). No difference in the 1-year cumulative overall survival was found (75.8±6.8% in 7.5 mg/kg arm vs. 73.7±4.6% in 10 mg/kg arm, P=0.192).
Conclusion
Compared with 10 mg/kg of ATG, the application of 7.5 mg/kg might reduce the viral infection after haploidentical HSCT and not increase the risk for severe aGVHD.
Session topic: E-poster
Keyword(s): ATG, CMV infection, EBV, Haploidentical stem cell transplantation
Type: Eposter Presentation
Background
Antithymocyteglobulin (ATG) has been widely used to prevent acute graft-versus-host disease (aGVHD) in recipients receiving haploidentical hematopoietic stem cell transplantation (HSCT). Notwithstanding, immunosuppressive effect of ATG increases the risk for infections, especially viral infection. Therefore, the optimal dose of ATG which elicits adequate immune suppression and limits the development of viral infection/reactivation is needed to be studied.
Aims
To evaluate the effect of different doses of ATG on post-transplant viral infection, this multicenter prospective study was conducted to compare EBV and CMV infection in haploidentical HSCT recipients receiving 7.5 mg/kg or 10 mg/kg of ATG. Besides, the incidence of aGVHD was compared between the two arms.
Methods
Between January 2013 and August 2015, 217 consecutive patients with hematological malignancies undergoing haploidentical HSCT were enrolled in 4 hospitals. One hundred and ten patients were randomized to receive a total dosage of 7.5 mg/kg of ATG and 107 were randomized to receive 10 mg/kg of ATG.
Results
The 1-year cumulative incidence of EBV infection were 30.7±6.0% in 7.5 mg/kg of ATG arm and 43.1±6.0% in 10 mg/kg arm (P=0.107). CMV infection were comparable in the two arms (7.5 mg/kg arm: 79.6±3.9% vs 10 mg/kg arm: 84.1±3.6%, P=0.188). Acute GVHD grade II to IV within 100 days occurred in 35.9±5.2% of the patients with 7.5 mg/kg ATG and 19.2±4.8% of those with 10 mg/kg ATG (P=0.004). The incidence of aGVHD grade III to IV within day 100 were 14.1±3.9% in 7.5 mg/kg arm and 7.3±3.3% in 10 mg/kg arm (P=0.072). No difference in the 1-year cumulative overall survival was found (75.8±6.8% in 7.5 mg/kg arm vs. 73.7±4.6% in 10 mg/kg arm, P=0.192).
Conclusion
Compared with 10 mg/kg of ATG, the application of 7.5 mg/kg might reduce the viral infection after haploidentical HSCT and not increase the risk for severe aGVHD.
Session topic: E-poster
Keyword(s): ATG, CMV infection, EBV, Haploidentical stem cell transplantation
Abstract: E1523
Type: Eposter Presentation
Background
Antithymocyteglobulin (ATG) has been widely used to prevent acute graft-versus-host disease (aGVHD) in recipients receiving haploidentical hematopoietic stem cell transplantation (HSCT). Notwithstanding, immunosuppressive effect of ATG increases the risk for infections, especially viral infection. Therefore, the optimal dose of ATG which elicits adequate immune suppression and limits the development of viral infection/reactivation is needed to be studied.
Aims
To evaluate the effect of different doses of ATG on post-transplant viral infection, this multicenter prospective study was conducted to compare EBV and CMV infection in haploidentical HSCT recipients receiving 7.5 mg/kg or 10 mg/kg of ATG. Besides, the incidence of aGVHD was compared between the two arms.
Methods
Between January 2013 and August 2015, 217 consecutive patients with hematological malignancies undergoing haploidentical HSCT were enrolled in 4 hospitals. One hundred and ten patients were randomized to receive a total dosage of 7.5 mg/kg of ATG and 107 were randomized to receive 10 mg/kg of ATG.
Results
The 1-year cumulative incidence of EBV infection were 30.7±6.0% in 7.5 mg/kg of ATG arm and 43.1±6.0% in 10 mg/kg arm (P=0.107). CMV infection were comparable in the two arms (7.5 mg/kg arm: 79.6±3.9% vs 10 mg/kg arm: 84.1±3.6%, P=0.188). Acute GVHD grade II to IV within 100 days occurred in 35.9±5.2% of the patients with 7.5 mg/kg ATG and 19.2±4.8% of those with 10 mg/kg ATG (P=0.004). The incidence of aGVHD grade III to IV within day 100 were 14.1±3.9% in 7.5 mg/kg arm and 7.3±3.3% in 10 mg/kg arm (P=0.072). No difference in the 1-year cumulative overall survival was found (75.8±6.8% in 7.5 mg/kg arm vs. 73.7±4.6% in 10 mg/kg arm, P=0.192).
Conclusion
Compared with 10 mg/kg of ATG, the application of 7.5 mg/kg might reduce the viral infection after haploidentical HSCT and not increase the risk for severe aGVHD.
Session topic: E-poster
Keyword(s): ATG, CMV infection, EBV, Haploidentical stem cell transplantation
Type: Eposter Presentation
Background
Antithymocyteglobulin (ATG) has been widely used to prevent acute graft-versus-host disease (aGVHD) in recipients receiving haploidentical hematopoietic stem cell transplantation (HSCT). Notwithstanding, immunosuppressive effect of ATG increases the risk for infections, especially viral infection. Therefore, the optimal dose of ATG which elicits adequate immune suppression and limits the development of viral infection/reactivation is needed to be studied.
Aims
To evaluate the effect of different doses of ATG on post-transplant viral infection, this multicenter prospective study was conducted to compare EBV and CMV infection in haploidentical HSCT recipients receiving 7.5 mg/kg or 10 mg/kg of ATG. Besides, the incidence of aGVHD was compared between the two arms.
Methods
Between January 2013 and August 2015, 217 consecutive patients with hematological malignancies undergoing haploidentical HSCT were enrolled in 4 hospitals. One hundred and ten patients were randomized to receive a total dosage of 7.5 mg/kg of ATG and 107 were randomized to receive 10 mg/kg of ATG.
Results
The 1-year cumulative incidence of EBV infection were 30.7±6.0% in 7.5 mg/kg of ATG arm and 43.1±6.0% in 10 mg/kg arm (P=0.107). CMV infection were comparable in the two arms (7.5 mg/kg arm: 79.6±3.9% vs 10 mg/kg arm: 84.1±3.6%, P=0.188). Acute GVHD grade II to IV within 100 days occurred in 35.9±5.2% of the patients with 7.5 mg/kg ATG and 19.2±4.8% of those with 10 mg/kg ATG (P=0.004). The incidence of aGVHD grade III to IV within day 100 were 14.1±3.9% in 7.5 mg/kg arm and 7.3±3.3% in 10 mg/kg arm (P=0.072). No difference in the 1-year cumulative overall survival was found (75.8±6.8% in 7.5 mg/kg arm vs. 73.7±4.6% in 10 mg/kg arm, P=0.192).
Conclusion
Compared with 10 mg/kg of ATG, the application of 7.5 mg/kg might reduce the viral infection after haploidentical HSCT and not increase the risk for severe aGVHD.
Session topic: E-poster
Keyword(s): ATG, CMV infection, EBV, Haploidentical stem cell transplantation
{{ help_message }}
{{filter}}